Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:BDRX NASDAQ:KALA NASDAQ:KPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.79+2.5%$0.98$0.57▼$3.85$25.74M0.2737,048 shs25,690 shsBDRXBiodexa Pharmaceuticals$6.02+1.5%$7.27$5.00▼$108.90$3.73M0.87169,260 shs60,295 shsKALAKALA BIO$18.62+9.5%$8.60$2.92▼$18.89$130.71M-1.81107,838 shs548,207 shsKPRXKiora Pharmaceuticals$2.64-2.2%$2.78$2.25▼$4.18$9.06M-0.68188,096 shs23,686 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-2.53%+5.48%-24.51%-35.29%-78.00%BDRXBiodexa Pharmaceuticals+3.31%+3.85%-15.16%-44.58%+592,999,900.00%KALAKALA BIO+11.33%+17.00%+128.49%+295.35%+182.86%KPRXKiora Pharmaceuticals-0.37%-1.10%+8.00%-10.60%-24.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.79+2.5%$0.98$0.57▼$3.85$25.74M0.2737,048 shs25,690 shsBDRXBiodexa Pharmaceuticals$6.02+1.5%$7.27$5.00▼$108.90$3.73M0.87169,260 shs60,295 shsKALAKALA BIO$18.62+9.5%$8.60$2.92▼$18.89$130.71M-1.81107,838 shs548,207 shsKPRXKiora Pharmaceuticals$2.64-2.2%$2.78$2.25▼$4.18$9.06M-0.68188,096 shs23,686 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-2.53%+5.48%-24.51%-35.29%-78.00%BDRXBiodexa Pharmaceuticals+3.31%+3.85%-15.16%-44.58%+592,999,900.00%KALAKALA BIO+11.33%+17.00%+128.49%+295.35%+182.86%KPRXKiora Pharmaceuticals-0.37%-1.10%+8.00%-10.60%-24.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 3.00Buy$3.30318.25% UpsideBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AKALAKALA BIO 3.20Buy$21.7516.81% UpsideKPRXKiora Pharmaceuticals 2.50Moderate Buy$10.00278.79% UpsideCurrent Analyst Ratings BreakdownLatest KPRX, KALA, BDRX, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $33.009/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.609/8/2025KALAKALA BIOMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$30.009/3/2025KALAKALA BIOLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/13/2025KPRXKiora PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.007/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ABDRXBiodexa Pharmaceuticals$470K7.94N/AN/A$2.91 per share2.07KALAKALA BIO$3.89M33.60N/AN/A$2.02 per share9.22KPRXKiora Pharmaceuticals$16.02M0.57$1.21 per share2.19$8.58 per share0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%9/25/2025 (Estimated)BDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/AN/AKALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)KPRXKiora Pharmaceuticals$3.60M-$2.91N/AN/AN/AN/A-47.17%-34.00%11/14/2025 (Estimated)Latest KPRX, KALA, BDRX, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025AKTXAkari Therapeutics-$0.09N/AN/AN/AN/AN/A8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A8/8/2025Q2 2025KPRXKiora Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$0.75 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19BDRXBiodexa Pharmaceuticals0.011.751.75KALAKALA BIO3.192.102.10KPRXKiora PharmaceuticalsN/A7.767.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BDRXBiodexa Pharmaceuticals17.51%KALAKALA BIO24.61%KPRXKiora Pharmaceuticals76.97%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%BDRXBiodexa Pharmaceuticals0.34%KALAKALA BIO8.32%KPRXKiora Pharmaceuticals0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableBDRXBiodexa Pharmaceuticals20620,000618,000Not OptionableKALAKALA BIO307.02 million6.44 millionNot OptionableKPRXKiora Pharmaceuticals103.43 million3.43 millionNot OptionableKPRX, KALA, BDRX, and AKTX HeadlinesRecent News About These CompaniesKiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 6, 2025 | theglobeandmail.comHC Wainwright Has Negative Outlook of KPRX Q3 EarningsSeptember 6, 2025 | americanbankingnews.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | finanznachrichten.deKiora Pharmaceuticals (NASDAQ:KPRX) Earns Buy Rating from HC WainwrightSeptember 3, 2025 | americanbankingnews.comKiora Pharmaceuticals Highlights at Ophthalmology ConferenceAugust 13, 2025 | msn.comKiora (KPRX) Q2 Revenue Falls 100%August 8, 2025 | theglobeandmail.comKiora Pharmaceuticals Advances Retinal Disease PipelineAugust 8, 2025 | tipranks.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 8, 2025 | finanznachrichten.deKiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 8, 2025 | finance.yahoo.comKiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal DiseasesAugust 8, 2025 | newsfilecorp.comNKiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular DiseaseJuly 22, 2025 | newsfilecorp.comNKiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should KnowJuly 16, 2025 | zacks.comkiora pharmaceuticals reports results of annual shareholder meetingJune 6, 2025 | investing.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | finanznachrichten.deKiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | newsfilecorp.comNKiora Pharmaceuticals Reports Q1 2025 Financial ResultsMay 30, 2025 | tipranks.comKiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027May 9, 2025 | newsfilecorp.comNKiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative VitreoretinopathyMay 5, 2025 | finance.yahoo.comKiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare ConferenceApril 4, 2025 | newsfilecorp.comNKiora Pharmaceuticals Advances Retinal Disease PipelineMarch 25, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPRX, KALA, BDRX, and AKTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$0.79 +0.02 (+2.47%) Closing price 03:59 PM EasternExtended Trading$0.79 +0.01 (+0.63%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Biodexa Pharmaceuticals NASDAQ:BDRX$6.02 +0.09 (+1.52%) Closing price 03:55 PM EasternExtended Trading$6.03 +0.01 (+0.17%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.KALA BIO NASDAQ:KALA$18.62 +1.62 (+9.53%) Closing price 04:00 PM EasternExtended Trading$18.58 -0.04 (-0.21%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Kiora Pharmaceuticals NASDAQ:KPRX$2.64 -0.06 (-2.22%) Closing price 03:59 PM EasternExtended Trading$2.70 +0.06 (+2.27%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
